Works matching DE "HETEROZYGOUS familial hypercholesterolemia"
Results: 78
Endothelial Dysfunction, But Not Structural Atherosclerosis, Is Evident Early in Children With Heterozygous Familial Hypercholesterolemia.
- Published in:
- Pediatric Cardiology, 2014, v. 35, n. 1, p. 63, doi. 10.1007/s00246-013-0742-0
- By:
- Publication type:
- Article
Let's Be Clear about Expected Cardiovascular Risk: A Commentary on the Massive Rise in LDL Cholesterol Induced by Carbohydrate Restriction in the Proposed "Lean Mass Hyper-Responder" Phenotype.
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
Heterozygous Familial Hyperlipidemia in a Fighter Pilot.
- Published in:
- Aerospace Medicine & Human Performance, 2021, v. 92, n. 10, p. 835, doi. 10.3357/AMHP.5906.2021
- By:
- Publication type:
- Article
Prediction of subtle left ventricular systolic dysfunction in homozygous and heterozygous familial hypercholesterolemia: Genetic analyses and speckle tracking echocardiography study.
- Published in:
- Echocardiography, 2018, v. 35, n. 9, p. 1289, doi. 10.1111/echo.14021
- By:
- Publication type:
- Article
Myocardial layer-specific analysis in patients with heterozygous familial hypercholesterolemia using speckle tracking echocardiography.
- Published in:
- Echocardiography, 2017, v. 34, n. 3, p. 390, doi. 10.1111/echo.13442
- By:
- Publication type:
- Article
Diagnostyka i leczenie heterozygotycznej postaci hipercholesterolemii rodzinnej u dzieci -- doniesienie wstępne.
- Published in:
- Pediatric Endocrinology / Endokrynologia Pediatryczna, 2013, v. 12, n. 3, p. 9
- By:
- Publication type:
- Article
Emerging Circulating Biomarkers in Atherosclerosis: From Molecular Mechanisms to Therapeutic Strategies.
- Published in:
- Biomolecules (2218-273X), 2022, v. 12, n. 6, p. 809, doi. 10.3390/biom12060809
- By:
- Publication type:
- Article
PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy.
- Published in:
- Biomolecules (2218-273X), 2022, v. 12, n. 4, p. 562, doi. 10.3390/biom12040562
- By:
- Publication type:
- Article
Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia—target attainment requires further increase of intensity.
- Published in:
- Pediatric Nephrology, 2018, v. 33, n. 7, p. 1199, doi. 10.1007/s00467-018-3906-6
- By:
- Publication type:
- Article
Gene therapy in cardiology: pioneering a new era in medical ethics and patient care.
- Published in:
- Expert Review of Clinical Pharmacology, 2025, v. 18, n. 1/2, p. 9, doi. 10.1080/17512433.2024.2448523
- By:
- Publication type:
- Article
Resilient Older Subjects with Heterozygous Familial Hypercholesterolemia, Baseline Differences and Associated Factors.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 9, p. 4831, doi. 10.3390/ijms25094831
- By:
- Publication type:
- Article
Unveiling Familial Hypercholesterolemia—Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 3, p. 1637, doi. 10.3390/ijms25031637
- By:
- Publication type:
- Article
Decreased Serum Stromal Cell-Derived Factor-1 in Patients with Familial Hypercholesterolemia and Its Strong Correlation with Lipoprotein Subfractions.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 20, p. 15308, doi. 10.3390/ijms242015308
- By:
- Publication type:
- Article
Sphingosine 1-Phosphate and Apolipoprotein M Levels and Their Correlations with Inflammatory Biomarkers in Patients with Untreated Familial Hypercholesterolemia.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 22, p. 14065, doi. 10.3390/ijms232214065
- By:
- Publication type:
- Article
Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study.
- Published in:
- Cardiovascular Drugs & Therapy, 2024, v. 38, n. 1, p. 119, doi. 10.1007/s10557-022-07386-0
- By:
- Publication type:
- Article
Monoclonal Anti-PCSK9 Antibodies: Real-World Data.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 15, p. 4543, doi. 10.3390/jcm13154543
- By:
- Publication type:
- Article
Risk Factors and Modifiers for Cardiovascular Disease Assessment of Patients with Heterozygous Familial Hypercholesterolaemia.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 8, p. 2270, doi. 10.3390/jcm13082270
- By:
- Publication type:
- Article
Familial hypercholesterolemia due to an heterozygous LDLR promoter mutation: a case report.
- Published in:
- Médicas UIS, 2024, v. 37, n. 3, p. 71, doi. 10.18273/revmed.v37n3-2024007
- By:
- Publication type:
- Article
Alirocumab: Pediatric First Approval.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Cholesterol lowering with inclisiran: a new chapter in the PCSK9 story book.
- Published in:
- European Heart Journal, 2023, v. 44, n. 2, p. 139, doi. 10.1093/eurheartj/ehac656
- By:
- Publication type:
- Article
Inclisiran in primary prevention: reality or fiction?
- Published in:
- European Heart Journal, 2022, v. 43, n. 48, p. 5058, doi. 10.1093/eurheartj/ehac653
- By:
- Publication type:
- Article
Underdiagnosis of familial hypercholesterolaemia: innovation is overdue.
- Published in:
- European Heart Journal, 2022, v. 43, n. 34, p. 3255, doi. 10.1093/eurheartj/ehab869
- By:
- Publication type:
- Article
Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy.
- Published in:
- European Heart Journal, 2021, v. 42, n. 32, p. 3063, doi. 10.1093/eurheartj/ehab424
- By:
- Publication type:
- Article
A Comprehensive Review of PCSK9 Inhibitors.
- Published in:
- Journal of Cardiovascular Pharmacology & Therapeutics, 2022, v. 27, p. 1, doi. 10.1177/10742484221100107
- By:
- Publication type:
- Article
МОНА ЛИЗА В НАШЕТО СЪВРЕМИЕ: ПАЦИЕНТ С ФАМИЛНА ХЕТЕРОЗИГОТНА ХИПЕРХОЛЕСТЕРОЛЕМИЯ.
- Published in:
- General Medicine / Obsta Medicina, 2022, v. 24, n. 4, p. 39
- By:
- Publication type:
- Article
МОНА ЛИЗА В НАШЕТО СЪВРЕМИЕ: ПАЦИЕНТ С ФАМИЛНА ХЕТЕРОЗИГОТНА ХИПЕРХОЛЕСТЕРОЛЕМИЯ.
- Published in:
- General Medicine / Obsta Medicina, 2022, v. 24, n. 4, p. 39
- By:
- Publication type:
- Article
Oral Porphyromonas gingivalis and Fusobacterium nucleatum Abundance in Subjects in Primary and Secondary Cardiovascular Prevention, with or without Heterozygous Familial Hypercholesterolemia.
- Published in:
- Biomedicines, 2022, v. 10, n. 9, p. 2144, doi. 10.3390/biomedicines10092144
- By:
- Publication type:
- Article
Effects of Lipid Lowering Therapy Optimization by PCSK9 Inhibitors on Circulating CD34+ Cells and Pulse Wave Velocity in Familial Hypercholesterolemia Subjects without Atherosclerotic Cardiovascular Disease: Real-World Data from Two Lipid Units.
- Published in:
- Biomedicines, 2022, v. 10, n. 7, p. N.PAG, doi. 10.3390/biomedicines10071715
- By:
- Publication type:
- Article
Recent Advances on Familial Hypercholesterolemia in Children and Adolescents.
- Published in:
- Biomedicines, 2022, v. 10, n. 5, p. 1043, doi. 10.3390/biomedicines10051043
- By:
- Publication type:
- Article
Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia.
- Published in:
- Biomedicines, 2022, v. 10, n. 4, p. 771, doi. 10.3390/biomedicines10040771
- By:
- Publication type:
- Article
The Progression of Treatment for Refractory Hypercholesterolemia: Focus on the Prospect of Gene Therapy.
- Published in:
- Frontiers in Genetics, 2022, v. 13, p. 1, doi. 10.3389/fgene.2022.911429
- By:
- Publication type:
- Article
Familial Hypercholesterolemia Prevalence Among Ethnicities—Systematic Review and Meta-Analysis.
- Published in:
- Frontiers in Genetics, 2022, v. 12, p. 1, doi. 10.3389/fgene.2022.840797
- By:
- Publication type:
- Article
Familial Hypercholesterolemia: Screening, Diagnosis, and Treatment.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Effectiveness and safety of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with familial hypercholesterolemia. Our experience in implementing the drug program of the Polish National Health Fund.
- Published in:
- Advances in Interventional Cardiology / Postępy w Kardiologii Interwencyjnej, 2022, v. 18, n. 2, p. 162, doi. 10.5114/aic.2022.118533
- By:
- Publication type:
- Article
Real‐world effectiveness of monoclonal antibody inhibitors of PCSK9 in patients with heterozygous familial hypercholesterolemia: A retrospective cohort study.
- Published in:
- Pharmacotherapy, 2024, v. 44, n. 9, p. 730, doi. 10.1002/phar.4609
- By:
- Publication type:
- Article
Oxidative stress-responsive apoptosis-inducing protein in patients with heterozygous familial hypercholesterolemia.
- Published in:
- Heart & Vessels, 2021, v. 36, n. 12, p. 1923, doi. 10.1007/s00380-021-01898-9
- By:
- Publication type:
- Article
The Role of Lipid Metabolism in Dyslipidemias and Atherosclerosis.
- Published in:
- Metabolites (2218-1989), 2024, v. 14, n. 11, p. 596, doi. 10.3390/metabo14110596
- By:
- Publication type:
- Article
Current concept and residual issues of lipoprotein(a) determination for a cardiovascular risk factor.
- Published in:
- European Journal of Clinical Investigation, 2022, v. 52, n. 1, p. 1, doi. 10.1111/eci.13700
- By:
- Publication type:
- Article
High-density lipoprotein-associated sphingosine-1-phosphate activity in heterozygous familial hypercholesterolaemia.
- Published in:
- European Journal of Clinical Investigation, 2017, v. 47, n. 1, p. 38, doi. 10.1111/eci.12699
- By:
- Publication type:
- Article
Case report: Heterozygous Familial Hypercholesterolemia (HeFH).
- Published in:
- 2012
- By:
- Publication type:
- Case Study
Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia.
- Published in:
- PLoS ONE, 2016, v. 11, n. 7, p. 1, doi. 10.1371/journal.pone.0158964
- By:
- Publication type:
- Article
Evaluation of miRNA-27a/b expression in patients with familial hypercholesterolemia.
- Published in:
- Archives of Medical Science, 2024, v. 20, n. 4, p. 1314, doi. 10.5114/aoms/150500
- By:
- Publication type:
- Article
Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol.
- Published in:
- Annals of Pharmacotherapy, 2023, v. 57, n. 3, p. 317, doi. 10.1177/10600280221105169
- By:
- Publication type:
- Article
Older Familial Hypercholesterolemia Patients with COVID-19.
- Published in:
- Gerontology, 2021, v. 67, n. 5, p. 608, doi. 10.1159/000514447
- By:
- Publication type:
- Article
An Interesting Case of Neonatal Atypical Hemolytic-Uremic Syndrome.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Metabolomic Approach to Screening Homozygotes in Chinese Patients with Severe Familial Hypercholesterolemia.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 2, p. 483, doi. 10.3390/jcm12020483
- By:
- Publication type:
- Article
Cardiovascular Risk Factors in Childhood and Adolescence.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 4, p. N.PAG, doi. 10.3390/jcm11041136
- By:
- Publication type:
- Article
Evaluation of Oxidative Stress Status in Familial Hypercholesterolemia.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 24, p. 5867, doi. 10.3390/jcm10245867
- By:
- Publication type:
- Article
Cataract Surgery in Elderly Subjects with Heterozygous Familial Hypercholesterolemia in Prolonged Treatment with Statins.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 16, p. 3494, doi. 10.3390/jcm10163494
- By:
- Publication type:
- Article